DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

CFRA Upgrades Boston Scientific to Strong Buy, Lowers Price Target to $47

CFRA analyst Kevin Huang upgrades Boston Scientific (NYSE:BSX) from Buy to Strong Buy and lowers the price target from $50 to $47.

Benzinga · 03/09/2020 19:28

CFRA analyst Kevin Huang upgrades Boston Scientific (NYSE:BSX) from Buy to Strong Buy and lowers the price target from $50 to $47.